Archives
-
NSP15 Inhibitor Screening: Thymopentin and Oleuropein
2026-10-07
A 2021 computational study screened a natural-product library against SARS-CoV-2 NSP15 and identified thymopentin and oleuropein as the strongest-ranked candidates. Molecular-dynamics analysis supported the persistence of the modeled complexes, but the findings remain hypothesis-generating because biochemical, cellular, animal, and clinical validation were not reported.
-
SGLT-2 Inhibitors: Class Effect or Drug Effect?
2026-10-06
A 2022 mouse study directly compared empagliflozin, dapagliflozin, and ertugliflozin in non-diabetic myocardial ischemia/reperfusion injury. Its findings suggest that infarct-size reduction was drug-dependent under the tested conditions, with protection associated with STAT-3 and PI3K signaling, mitochondrial preservation, and altered upstream mediators rather than SGLT-2 inhibition alone.
-
Wnt/NR2F2 and Platinum Resistance in Brain Metastasis
2026-10-06
Liu and colleagues linked acquired platinum resistance in lung cancer-derived brain metastatic cells to high glutathione consumption, GPX4/GSTM1 activity, and suppression of ferroptosis. Their evidence supports a Wnt/NR2F2/GPX4 regulatory model, while remaining primarily preclinical and requiring validation across broader patient populations and tumor contexts.
-
LGK-974 and PORCN Inhibition: Evidence and Limits
2026-10-05
LGK-974 is a research-stage PORCN inhibitor used to study ligand-dependent Wnt signaling. This overview separates supplier-reported pharmacology from peer-reviewed evidence, explains how PORCN inhibition may inform Wnt-driven cancer research, and examines what the 2025 pancreatic cancer study does—and does not—show about LGK-974.
-
H4K12 Lactylation and SLFN5 in TNBC
2026-10-05
A 2024 Cellular Signalling study connects lactate-associated histone H4K12 lactylation with SLFN5 downregulation and malignant progression in triple-negative breast cancer. Its integrated tissue, cellular, chromatin, reporter, and in vivo evidence supports a model in which metabolic reprogramming influences apoptosis through an epigenetic regulatory axis, while also leaving important questions about specificity and clinical translation.
-
Five Questions About FXR Condensates and Fluorescence
2026-10-04
This evidence-focused overview explains what the 2024 FXR–coronavirus study shows, what fluorescence can and cannot establish, how an Alexa Fluor 488 conjugated secondary antibody fits into interpretation, and where the findings should not be extrapolated.
-
SFRP1, Wnt/β-Catenin, and Oral Fibrosis
2026-10-03
A 2024 study connected reduced SFRP1 with neutrophil infiltration, collagen accumulation, and Wnt/β-catenin activation in an arecoline-induced mouse model of oral submucous fibrosis. Its combination of tissue-level correlation, SFRP1 overexpression, and pathway-activation reversal supports a mechanistic model, while the preclinical design limits direct clinical translation.
-
Shenqi Fuzheng and SRC/PI3K/AKT in Glioma
2026-10-01
This study integrates network pharmacology with cell-based and mouse experiments to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its central contribution is the identification and experimental support of SRC/PI3K/AKT signaling as a candidate mechanism linking a multi-component herbal formulation to cell-cycle arrest, reduced epithelial–mesenchymal transition features, and tumor suppression.
-
LGK-974 (Porcupine Inhibitor) for Reliable Assays
2026-10-01
This scenario-driven guide explains how LGK-974 (Porcupine Inhibitor), SKU B2307, can improve the interpretability of viability, proliferation, and Wnt-pathway experiments. It connects product-specific handling data with pathway biomarkers, assay controls, and published evidence for more reproducible laboratory decisions.
-
TRIM46 Regulation During Axon Formation
2026-09-30
The reference study shows that TRIM46 is controlled by coordinated transcriptional, alternative-splicing, nonsense-mediated decay, and protein-stability mechanisms during axon formation. Its findings reframe TRIM46 expression as a multilayered developmental checkpoint rather than a simple marker of neuronal polarity, with practical implications for separating RNA abundance, protein activity, and axonal organization in experimental systems.
-
HLY78: A Strategic Wnt/β-Catenin Research Lever
2026-09-30
HLY78 offers a ligand-dependent way to increase Wnt/β-catenin signaling by targeting the Axin DIX domain. This thought-leadership analysis connects its developmental evidence with SFRP1-mediated inhibition in oral submucous fibrosis, outlining practical validation strategies while separating promising hypotheses from clinical conclusions.
-
Urolithin A in Mitochondrial-Fibrosis Research
2026-09-29
Use Urolithin A to test whether mitochondrial quality control reshapes hepatic stellate cell metabolism, while keeping glutamine–GDH–SIRT4 biology as a mechanistic comparator. This workflow separates evidence-supported metabolic findings from hypothesis-generating applications in fibrosis, aging, skeletal muscle, and immune-cell research.
-
Biodegradable Polyesters for VEGF mRNA Delivery
2026-09-29
The reference study develops arginine- and lysine-functionalized three-armed biodegradable polyesters as alternatives to persistent cationic lipids in VEGF mRNA lipid nanoparticles. Its main finding is that arginine-modified formulations combine efficient mRNA delivery with reactive oxygen species scavenging and nitric oxide release, supporting angiogenesis in critical limb ischemia models.
-
Solanesol B8776: Practical Workflow Guide
2026-09-28
Solanesol (B8776) is a hydrophobic polyisoprenoid alcohol for controlled biochemical and membrane-related research workflows. It should be prepared in DMSO, used with solvent-matched controls, and kept out of water- or ethanol-based systems unless a validated formulation step has been established.
-
LGK-974: From Wnt Biology to Bone Disease
2026-09-28
LGK-974 is a potent PORCN inhibitor that suppresses secretion-dependent Wnt signaling. This article examines what a 2025 sclerosteosis study reveals about pathway dependence, tissue context, and how to interpret LGK-974 experiments beyond oncology.